Table 3. Association of Adage patients' characteristics including xaban plasma concentration and peak height (using STG-ThromboScreen reagent without thrombomodulin) .
| Covariates | Univariate | Multivariate | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| T max | T min | T max | T min | |||||||
| Effect | % | p | Effect | % | p | Effect | p | Effect | p | |
| Rivaroxaban | ||||||||||
| Plasma concentrations |
+23.9%
a
[−11.4; 73.2] |
8.4% | 0.537 |
+38.7%
a
[12.4;71.1] |
22.1% | 0.0018 |
–5.0%
a
[−27.9; 25.2] |
0.700 |
+21.0%
a
[−4.0; 52.4] |
0.103 |
| Creatinine clearance |
−12.8%
b
[−26.3; 3.0] |
22.9% | 0.027 |
−6.1%
b
[−16.2; 5.2 ] |
3.2% | 0.184 |
−16.4%
b
[−26.3; −5.0] |
0.0085 |
−6.76%
b
[−15.5; 2.8] |
0.156 |
| Heart failure | −37.5% [−59.8; −2.7] |
19.34% | 0.041 | −31.4% [−52.2; −1.7] |
10.8% | 0.055 | −22.3% [−45.0; 9.8] |
0.143 | −12.7% [−37.7; 22.4] |
0.422 |
| Amiodarone c | N.A c | N.A c . | N.A. | −51.5% [−70.1; −21.2] |
12.7% | 0.014 | N.A. c | N.A. c | −44.6%** [−75.1; 23.2] |
0.228 |
| Apixaban | ||||||||||
| Plasma concentrations |
+80.2%
a
10.0; 195.0] |
22.6% | 0.022 |
37.1%
a
13.1; 66.2] |
20.8% | 0.0005 |
+86.8%
a
[−0.48; 250.5] |
0.052 |
+32.7%
a
[8.28; 62.59] |
0.0074 |
| Creatinine clearance |
+0.42%
b
[4.70; 36.9] |
0.08% | 0.903 |
1.7%
b
[−10.7; 15.8] |
0.49% | 0.566 |
+2.4%
b
[−17.9; 27.8] |
0.825 |
−1.9%
b
[−13.4; 11.1] |
0.753 |
| Heart failure | −26.7% [−66.7; 61.4] |
1.8% | 0.426 | 3.2% [−30.5; 53.3] |
0.01% | 0.935 | −9.2% [−62.9; 122.6] |
0.826 | +0.84% [−30.8; 46.9] |
0.965 |
| Amiodarone c | +3.7% [−58.7; 160.1] |
0.5% | 0.936 | −37.2% [−60.0; −1.5] |
6.30% | 0.043 | −26.0% [−91.8; 564.1] |
0.759 | −57.47% [−83.2; 7.9] |
0.129 |
Note: Significance threshold: p < 0.05, bold values.
a
For halved concentrations.
b
Per decrease of 10 mL/min.
c
N.A = not available (number of values from patients on amiodarone at T max < 5).